The clinically explored KDM1A inhibitor GSK-LSD1 has been reported to inhibit the NF-κB-dependent production of cytokines (TNFα, IL-6, IL-1) by increasing histone H3K4me2 and H3K9me2 in LPS-induced mastitis [40]. Here, IL1B is linked to mastitis.